12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Clinical News  |  Preclinical Results

Circadian Technologies preclinical data

In a mouse model of orthotopic prostate cancer, VGX-100 significantly inhibited primary tumor growth and reduced the incidence of metastasis to...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >